EX-99.3 6 factsheet.htm FACT SHEET- WORD
PAGE 1
Investor Fact Sheet
Ticker Symbol: NASDAQ: CEMI
www.chembio.com

Business Summary & Investment Highlights
Chembio Diagnostics, Inc., (Chembio), through its wholly-owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care testing (POCT) products.  Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create significant new revenue streams that will add to Chembio's core business of rapid HIV tests.
·
Four Consecutive Years of Profitability and Revenue Growth.
·
Strategy is to create core business of public health products to be complemented by OEM and selected out-licensing opportunities.
·
Robust pipeline of POCT products for infectious diseases based on Chembio's patented DPP® technology.
·
Products developed on DPP® platform include oral fluid HIV test approved by FDA in December 2012.   Unique multiplex HIV-Syphilis test will be submitted and undergo US FDA regulatory evaluations in 2013.  Several other products and collaborations in pipeline.
·
Unique opportunity to participate in nascent U.S. market for OTC HIV tests with multiple product offerings.
·
Five DPP® products approved and successfully launched in Brazil public health pursuant to supply and license agreement; potential of at least $23MM in revenues; $14MM realized to date.
Selected Financial Information
Stock Information
Ticker Symbol: CEMI
Price 10/31/2013:   $3.72
52 Week High:     $5.80
52 Week Low:   $3.00
Outstanding Shares (MM): 9.32
Market Capitalization (MM): $34.69
Fully Diluted (FD) Shares (MM): 9.99
Management Holding-FD (MM): 1.55
Average Daily Vol. (3 Mos):  40,000

Major Beneficial Holders Beneficial Shares Owned (MM)
Lawrence Siebert: 820
Wellington Management Company, LLP: 671  12/31/12 Report Date
Norman H. Pessin: 450
 
  
   
 
Balance Sheet Data ($000s)
  
Sept '13
    
Dec.'12
  
Cash
  
$
8,046
    
$
2,952
  
Accts. Receivable
    
5,505
      
4,821
  
Inventories
    
3,747
      
2,488
  
Other Current Assets
    
709
      
747
  
Total Current Assets
    
18,007
      
11,008
  
Net Fixed Assets
    
1,823
      
1,428
  
Other Assets
    
4,496
      
4,899
  
Total Assets
    
24,326
      
17,335
  
Total Current Liab.
    
3,935
      
3,378
  
Total Other Liab.
    
-
      
82
  
Total Liabilities
    
3,935
      
3,460
  
Stockholders' Equity
    
20,391
      
13,875
  
Total Liabilities & Stockholders' Equity
  
$
24,326
    
$
17,335
  
 
                


Selected Comparative Historical Financial Data
    
   
   
   
   
   
 
Quarter/Year Ended
    
For the Quarter Ended
    
For the Six Months Ended
    
For the Years Ended
  
$
(000s
)
  
Q3'13
    
Q3'12
    
Q3'13
    
Q3'12
      
2012
      
2011
      
2010
      
2009
  
Total Revenues
    
$
9,617
    
$
5,007
    
$
21,689
    
$
17,745
    
$
25,611
    
$
19,388
    
$
16,705
    
$
13,834
  
Cost of sales
      
5,561
      
3,278
      
12,658
      
10,112
      
14,821
      
9,998
      
8,604
      
7,974
  
Gross Profit
      
4,056
      
1,729
      
9,031
      
7,633
      
10,790
      
9,390
      
8,101
      
5,860
  
         
42.2
%
    
34.5
%
    
41.6
%
    
43.0
%
    
42.1
%
    
48.4
%
    
48.5
%
    
42.4
%
R&D Expense
      
1,602
      
1,006
      
4,148
      
3,364
      
4,486
      
4,878
      
2,586
      
2,884
  
SG&A Expense
      
1,380
      
1,208
      
3,702
      
3,522
      
4,852
      
3,424
      
2,941
      
2,659
  
Operating Income (Loss)
      
1,074
      
(485
)
    
1,181
      
747
      
1,452
      
1,088
      
2,574
      
317
  
Other Inc. (Expense)
      
1
      
(1
)
    
11
      
(2
)
    
(1
)
    
(12
)
    
(15
)
    
(8
)
Net Income (Loss)
      
1,075
      
(486
)
    
1,192
      
745
      
1,451
      
1,076
      
2,559
      
309
  
Inc Tax (Ben.) Prov.
      
359
      
(193
)
    
399
      
295
      
509
      
(5,133
)
    
-
      
-
  
Net Income (Loss)
    
$
716
    
$
(293
)
  
$
793
    
$
450
    
$
942
    
$
6,209
    
$
2,559
    
$
309
  
Net Income (Loss) - per Share
    
$
0.08
    
$
0.04
      
0.09
      
0.06
    
$
0.11
    
$
0.73
    
$
0.29
    
$
0.03
  
Wt. Avg. No. Shares (Millions)
      
9.235
      
8.001
      
8.887
      
7.974
      
8.615
      
8.556
      
8.865
      
9.380
  
Working capital
    
$
14,072
    
$
7,630
    
$
14,072,
    
$
7,630
    
$
7,630
    
$
6,134
    
$
4,560
    
$
1,494
  
Total assets
      
24,326
      
17,335
      
24,326
      
17,335
      
17,335
      
15,486
      
9,086
      
6,315
  
Total liabilities
      
3,935
      
3,461
      
3,935
      
3,461
      
3,460
      
2,991
      
3,277
      
3,227
  
Equity
      
20,391
      
13,875
      
20,391
      
13,875
      
13,875
      
12,495
      
5,809
      
3,088
  

 
 Chembio Diagnostics, Inc.
Investor Relations
 Company Contact
 3661 Horseblock Road
Vida Strategic Partners
Susan Norcott
 Medford, NY 11763
Stephanie C. Diaz
 631-924-1135 x125
 Ph. 631-924-1135
(415) 675-7401
 snorcott@chembio.com
 Fax 631-924-2065
sdiaz@vidasp.com
 
 www.chembio.com
 
 
 
PAGE 2 – See Graphics

DPP® Technology
Competitive Advantages For POC Testing

• Improved Sensitivity - enabled by more efficient binding method
• Easier Multiplexing - due to even and direct distribution of sample to multiple test lines
• Enhanced Sample Control - as result of independent sample migration path
• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results

Chembio's Dual Path Platform (DPP®) Patented in 2007  (see graphic)
 
 
Chembio's Lateral Flow Rapid HIV Tests Marketed Exclusively in the USA by Alere North America, Inc.
 
Senior Management Team
Lawrence A. Siebert, Chairman & CEO, over 25 years of management and financing experience
Richard J. Larkin, CFO, over 25 years of operational and financial experience
Javan Esfandiari, SVP R&D, over 15 years of experience in development of in-vitro point-of- care products
Sharon Klugewicz, COO, over 20 years of experience with Pall Corp.

Independent Members of Board of Directors
Katherine Davis - Former Lieutenant Governor and numerous other leadership positions for the State of Indiana; former senior executive of Cummins, Inc. (NYSE:CMI)
Dr. Gary Meller - Broad experience in medical and information technology and pharmaceutical product development
Dr. Barbara DeBuono – Former New York Commissioner of Health and Rhode Island Director of Health; other positions in domestic and international medical services
Dr. Peter Kissinger – Has founded and/or led 3 biotechnology and/or biomedical technology companies, including a publicly-traded NASDAQ company

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostic's Inc. most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. –Nov. 2013.